ArticleJapanese journal of cancer research : Gann1997
Anti-tumor efficacy of paclitaxel against human lung cancer xenografts.
Article in Japanese journal of cancer research : Gann, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 64 citations in OpenAlex.
- Paclitaxel compromises nuclear integrity in interphase through SUN2-mediated cytoskeletal coupling.Journal of cell science · 2026Article
- A mouse model of lung cancer induced via intranasal injection for anticancer drug screening and evaluation of pathology.FEBS open bio · 2023Article
- How to Improve SBRT Outcomes in NSCLC: From Pre-Clinical Modeling to Successful Clinical Translation.Cancers · 2022Review
- A novel, small peptide with activity against human pancreatic cancer.American journal of cancer research · 2020Article
- Potent and broad anticancer activities of leaf extracts fromAmerican journal of cancer research · 2020Article
- Ambient fine particulate matter inhibits 15-lipoxygenases to promote lung carcinogenesis.Journal of experimental & clinical cancer research : CR · 2019Article
- Review
- Targeting the Golgi apparatus to overcome acquired resistance of non-small cell lung cancer cells to EGFR tyrosine kinase inhibitors.Oncotarget · 2018Article
- Kamishoyosan and Shakuyakukanzoto promote recovery from paclitaxel-induced neurite retraction in PC12 cells.Journal of pharmaceutical health care and sciences · 2017Article
- Absence of lung fibrosis after a single pulmonary delivery of lipid nanocapsules in rats.International journal of nanomedicine · 2017Article
- Disulfide-crosslinked nanomicelles confer cancer-specific drug delivery and improve efficacy of paclitaxel in bladder cancer.Nanotechnology · 2016Article
- Therapeutic Enzyme-Responsive Nanoparticles for Targeted Delivery and Accumulation in Tumors.Advanced materials (Deerfield Beach, Fla.) · 2015Article
- Therapeutic potential of targeting protein for Xklp2 silencing for pancreatic cancer.Cancer medicine · 2015Article
- SapC-DOPS nanovesicles as targeted therapy for lung cancer.Molecular cancer therapeutics · 2015Article
- Preclinical Murine Models for Lung Cancer: Clinical Trial Applications.BioMed research international · 2015Review
- Gambogic acid synergistically potentiates cisplatin-induced apoptosis in non-small-cell lung cancer through suppressing NF-κB and MAPK/HO-1 signalling.British journal of cancer · 2014Article
- The use of porous scaffold as a tumor model.International journal of biomaterials · 2013Article
- A novel bioluminescence orthotopic mouse model for advanced lung cancer.Radiation research · 2011Article
- Correlation between cytotoxic activities and reduction potentials of heterocyclic quinones.Molecules (Basel, Switzerland) · 2010Article
- Low-dose paclitaxel prior to intratumoral dendritic cell vaccine modulates intratumoral cytokine network and lung cancer growth.Clinical cancer research : an official journal of the American Association for Cancer Research · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We examined paclitaxel for anti-tumor activity against human lung cancer xenografts in nude mice and compared its efficacy with that of cisplatin, currently a key drug for lung cancer chemotherapy. Five non-small cell lung cancers (A549, NCI-H23, NCI-H226, NCI-H460 and NCI-H522) and 2 small cell lung cancers (DMS114 and DMS273) were chosen for this study, since these cell lines have been well characterized as regards in vitro and in vivo drug sensitivity. These cells were exposed to graded concentrations of paclitaxel (0.1 to 1000 nM) for 48 h. The 50% growth-inhibitory concentrations (GI50) for the cell lines ranged from 4 to 24 nM, which are much lower than the achievable peak plasma concentration of paclitaxel. In the in vivo study, 4 cell lines (A549, NCI-H23, NCI-H460, DMS-273) were grown as subcutaneous tumors xenografts in nude mice. Paclitaxel was given intravenously as consecutive daily injections for 5 days at the doses of 24 and 12 mg/kg/day. Against every xenograft, paclitaxel produced a statistically significant tumor growth inhibition compared to the saline control. Paclitaxel at 24 mg/kg/day was more effective than cisplatin at 3 mg/kg/day with the same dosing schedule as above, although the toxicity of paclitaxel was similar to or rather lower than that of cisplatin, in terms of body weight loss. In addition, paclitaxel showed potent activity against 2 other lung cancer xenografts (NCI-H226 and DMS114). Therefore, paclitaxel showed more effective, wider-spectrum anti-tumor activity than cisplatin in this panel of 6 lung cancer xenografts. These findings support the potential utility of paclitaxel in the treatment of human lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.